Microvolt T-wave alternans testing provides a reliable means of guiding anti-arrhythmic therapy

Author(s)
Hohnloser, Stefan H.; Cohen, Richard J.
Thumbnail
Download20120407-Letter to American Heart Journal.pdf (15.55Kb)
OPEN_ACCESS_POLICY
Terms of use
Creative Commons Attribution-Noncommercial-Share Alike 3.0 http://creativecommons.org/licenses/by-nc-sa/3.0/
Metadata
Show full item record
Abstract
Gupta et al1 present a meta-analysis and conclude that microvolt T-wave alternans testing (MTWA) does not modify risk of sudden cardiac death (SCD) sufficiently for clinical use. Their analysis involves a number of methodological limitations. The authors included in their primary analysis numerous surrogates for sudden cardiac death (SCD) such as ICD therapy, cardiac mortality and total mortality.
Date issued
2012-10
URI
http://hdl.handle.net/1721.1/79792
Department
Whitaker College of Health Sciences and Technology; Harvard University--MIT Division of Health Sciences and Technology
Journal
American Heart Journal
Publisher
Elsevier B.V.
Citation
Hohnloser, Stefan H., and Richard J. Cohen. Microvolt T-wave Alternans Testing Provides a Reliable Means of Guiding Anti-arrhythmic Therapy. American Heart Journal 164, no. 4 (October 2012): e7.
Version: Author's final manuscript
ISSN
00028703
Collections